Company: TAK
Filing Date: 2025-05-08
Form Type: 6-K
Source: 0001395064-25-000048
Chunk: 34

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-05-08
Form: 6-K
Chunk 34
---
                              | -100,375 |     |     |   -112,984 |
| Dividends paid                                                                                |     |                              | -287,188 |     |     |   -302,498 |
| Repayments of lease liabilities                                                               |     |                              |  -54,586 |     |     |    -45,174 |
| Other, net                                                                                    |     |                              |  -26,102 |     |     |    -16,647 |
| Net cash used in financing activities                                                         |     |                              | -354,416 |     |     |   -751,425 |
| Net decrease in cash and cash equivalents                                                     |     |                              | -101,934 |     |     |    -61,303 |
| Cash and cash equivalents at the beginning of the year                                        |     |                              |  533,530 |     |     |    457,800 |
| Effects of exchange rate changes on cash and cash equivalents                                 |     |                              |   26,204 |     |     |    -11,385 |
| Cash and cash equivalents at the end of the year                                              |     |                              |  457,800 |     |     |    385,113 |

<div align='center'>27</div>

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Fiscal Year

Ended March 31, 2025 (Consolidated)

### (6) Notes to Consolidated Financial Statements
(Going Concern Assumption)

No events to be noted for this purpose.

(Significant Items that Form the Basis of Preparing the Consolidated Financial Statements)

1. Basis of Preparation

(1) Compliance

Since Takeda satisfies all of the criteria of the "Specified Company" prescribed in Article 1-2 of the Regulation On Terminology, Forms, and Preparation Methods of Consolidated Financial Statements (Ministry of Finance Order No.28, 1976 "Regulations for Consolidated Financial Statements"), the consolidated financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS") pursuant to the provision of Article 312 of the Regulations for Consolidated Financial Statements.

(2) Basis of Measurement

The consolidated financial statements have been prepared on a historical cost basis, except for certain assets and liabilities recorded at fair value including equity investments, derivative financial instruments, and financial assets and liabilities associated with contingent consideration arrangements, and the application of hyperinflationary accounting at